Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age (CP149)

13 lipca 2012 zaktualizowane przez: MedImmune LLC

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV), in Healthy Children 6 to <24 Months of Age

The overall objective of the MEDI-534 clinical development program is to evaluate the safety, efficacy and tolerability of MEDI-534 for the prevention of serious RSV and PIV3 disease in young infants.

Przegląd badań

Szczegółowy opis

The primary objective of this study is to describe the safety and tolerability of multiple doses of MEDI-534 at 10^4, 10^5, or 10^6 TCID50 when administered to RSV and PIV3 seronegative children 6 to <24 months of age.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

49

Faza

  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Arkansas
      • Conway, Arkansas, Stany Zjednoczone, 72033
        • Arkansas Pediatric Research Division
      • Little Rock, Arkansas, Stany Zjednoczone, 72205
        • Arkansas Pediatric Clinic
    • Colorado
      • Aurora, Colorado, Stany Zjednoczone, 80045
        • The Children's Hospital
    • Florida
      • Miami, Florida, Stany Zjednoczone, 33155
        • Miami Children's Hospital
      • Palm Beach Gardens, Florida, Stany Zjednoczone, 33410
        • Pediatric Partners
    • Georgia
      • Dalton, Georgia, Stany Zjednoczone, 30721
        • North Georgia Clinical Research Center
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60612
        • University Consultants in Allergy and Immunology
      • Chicago, Illinois, Stany Zjednoczone, 61614
        • Children's Memorial Hospital
    • Maryland
      • Baltimore, Maryland, Stany Zjednoczone, 21201
        • University of Maryland, Baltimore
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02111
        • Tufts-New England Medical Center
    • Missouri
      • Bridgeton, Missouri, Stany Zjednoczone, 63044
        • Craig A. Spiegel, MD
    • Nebraska
      • Omaha, Nebraska, Stany Zjednoczone, 68134
        • Meridian Clinical Research, LLC
    • New York
      • Binghamton, New York, Stany Zjednoczone, 13901
        • United Medical Associates
      • Mineola, New York, Stany Zjednoczone, 11501
        • Withrop University Hospital
      • Syracuse, New York, Stany Zjednoczone, 13210
        • SUNY Upstate Medical University
    • Ohio
      • Cincinnati, Ohio, Stany Zjednoczone, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Stany Zjednoczone, 44109
        • MetroHealth Medical Center
      • Cleveland, Ohio, Stany Zjednoczone, 44106
        • University Hospitals Case Medical Center
      • Toledo, Ohio, Stany Zjednoczone, 43608
        • St. Vincent Mercy Medical Center Mercy Children's Hospital
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15241
        • Primary Physicians Research, Inc.
    • South Dakota
      • Sioux Falls, South Dakota, Stany Zjednoczone, 57117
        • Sanford Children's Specialty Clinic
    • Tennessee
      • Nashville, Tennessee, Stany Zjednoczone, 37232
        • Vanderbilt University Medical Center
    • Texas
      • Houston, Texas, Stany Zjednoczone, 77030
        • University of Texas Health Science Center of Houston Medical School
    • Utah
      • Ogden, Utah, Stany Zjednoczone, 84405
        • Bear Care Pediatrics
      • South Jordan, Utah, Stany Zjednoczone, 84095
        • Copperview Medical Center
    • Virginia
      • Richmond, Virginia, Stany Zjednoczone, 23219
        • Virginia Commonwealth University
      • Vienna, Virginia, Stany Zjednoczone, 22180
        • Advanced Pediatrics
    • Washington
      • Spokane, Washington, Stany Zjednoczone, 99202
        • Rockwood Clinic Research Center
    • West Virginia
      • Huntington, West Virginia, Stany Zjednoczone, 25701
        • Marshall University Joan C. Edwards School of Medicine
      • Morgantown, West Virginia, Stany Zjednoczone, 26506
        • West Virginia University Health Science Center

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

6 miesięcy do 1 rok (Dziecko)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Male or female whose age on the day of randomization is 6 to <24 months (reached 6th month birthday and not yet reached 2nd year birthday)
  • Subject is seronegative to both RSV and PIV3 at screening
  • Subject was the product of normal full term pregnancy (defined as >36 weeks gestation)
  • Subject is in general good health
  • Subject's legal representative is available by telephone
  • Written informed consent and HIPAA authorization (if applicable) obtained from the subject's legal representative
  • Subject's legal representative is able to understand and comply with the requirements of the protocol as judged by the investigator
  • Subject is available to complete the follow-up period, which will be through the end of RSV season (provisionally defined as 01/Apr for the United States) or 180 days after the final dose of study vaccine, whichever is later
  • Subject's legal representative must be willing and able to bring the subject to the study site for evaluation of respiratory illness in accordance with the protocol

Exclusion Criteria:

  • Any fever (equal to or greater than 100.4°F [equal to or greater than 38.0°C], regardless of route) or lower respiratory illness (Section 4.1.2) within 7 days prior to randomization
  • Moderate or severe nasal congestion that in the investigator's opinion could prevent intranasal delivery of vaccine
  • Any drug therapy (chronic or other) within 7 days prior to randomization or expected receipt through the protocol-specified blood collection 28 days after each study vaccine dosing, except that infrequent use of over-the-counter medications such as pain relievers are permitted according to the judgment of the investigator
  • Any current or expected receipt of immunosuppressive agents including steroids (2 mg/kg per day of prednisone or its equivalent, or equal to or greater than 20 mg/day if the subject weighs >10 kg, given daily or on alternate days for equal to or greater than 14 days); children in this category should not receive study vaccine until immunosuppressive agents including corticosteroid therapy have been discontinued for equal to or greater than 30 days; the use of topical steroids is permitted according to the judgment of the investigator
  • History of receipt of blood transfusion or expected receipt through 30 days following final study vaccine dosing
  • History of receipt of immunoglobulin products or expected receipt through 30 days after study vaccine dosing
  • Receipt of any investigational drug within 60 days prior to randomization or expected receipt through 30 days after final study vaccine dosing
  • Receipt of any live virus vaccine (excluding rotavirus vaccine) within 28 days prior to randomization or expected receipt within a 28-day window around any study vaccine dose
  • Receipt of any inactivated (i.e., non-live) vaccine or rotavirus vaccine within 14 days prior to randomization or expected receipt within a 14-day window around any study vaccine dose
  • Known or suspected immunodeficiency, including HIV
  • Living in the same home or enrolled in the same classroom at day care with infants <24 months of age (only one child per household may be enrolled into the study)
  • Contact with pregnant caregiver
  • A household contact who is immunocompromised; the subject should also avoid close contact with immunocompromised individuals for at least 30 days after any study vaccine dose
  • A household contact who is a health care provider in contact with immunocompromised patients or who is a day care provider for infants under the age of 6 months
  • History of allergic reaction to any component of the study vaccine
  • Previous medical history, or evidence, of an intercurrent or chronic illness that, in the opinion of the investigator, may compromise the safety of the subject
  • Known or suspected active or chronic hepatitis infection
  • History of medical diagnosis of asthma, reactive airway disease, wheezing requiring medication, cystic fibrosis, bronchopulmonary dysplasia, chronic pulmonary disease, medically confirmed apnea, hospitalization for respiratory illness or mechanical ventilation
  • Family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study
  • Any condition that, in the opinion of the investigator, might interfere with study vaccine evaluation

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: 1
MEDI-534 at 10^4 TCID50 at 0, 2, and 4 months (Nasal spray)
Multiple doses of MEDI-534 or Placebo at 10^4 TCID50
Multiple doses of MEDI-534 or Placebo at 10 ^5 TCID50.
Multiple doses of MEDI-534 or Placebo at 10^6 TCID50.
Aktywny komparator: 2
MEDI-534 at 10^5 TCID50 at 0, 2, and 4 months (Nasal Spray)
Multiple doses of MEDI-534 or Placebo at 10^4 TCID50
Multiple doses of MEDI-534 or Placebo at 10 ^5 TCID50.
Multiple doses of MEDI-534 or Placebo at 10^6 TCID50.
Aktywny komparator: 3
MEDI-534 at 10^6 TCID50 at 0, 2, and 4 months (Nasal Spray)
Multiple doses of MEDI-534 or Placebo at 10^4 TCID50
Multiple doses of MEDI-534 or Placebo at 10 ^5 TCID50.
Multiple doses of MEDI-534 or Placebo at 10^6 TCID50.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Number of Participants With Adverse Events (AEs) After Dose 1
Ramy czasowe: Days 0-28 after Dose 1 (Dose 1 was on Day 0)
Unsolicited AEs reported by 1 or more participants in either treatment group through 28 days post Dose 1.
Days 0-28 after Dose 1 (Dose 1 was on Day 0)
Number of Participants With AEs After Dose 2
Ramy czasowe: Days 0-28 after Dose 2 (Dose 2 was on Day 48-64)
Unsolicited AEs reported by 1 or more participants in either treatment group through 28 days post Dose 2.
Days 0-28 after Dose 2 (Dose 2 was on Day 48-64)
Number of Participants With AEs After Dose 3
Ramy czasowe: Days 0-28 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Unsolicited AEs reported by 1 or more participants in either treatment group through 28 days post Dose 3.
Days 0-28 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Number of Participants With Solicited Adverse Events (SEs) After Dose 1
Ramy czasowe: Days 0-28 after Dose 1 (Dose 1 was on Day 0)
The SEs for this study included fever ≥ 100.4°F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, laryngitis, and epistaxis.
Days 0-28 after Dose 1 (Dose 1 was on Day 0)
Number of Participants With SEs After Dose 2
Ramy czasowe: Days 0-28 after Dose 2 (Dose 2 was on Day 48-64)
The SEs for this study included fever ≥ 100.4°F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, laryngitis, and epistaxis.
Days 0-28 after Dose 2 (Dose 2 was on Day 48-64)
Number of Participants With SEs After Dose 3
Ramy czasowe: Days 0-28 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
The SEs for this study included fever ≥ 100.4°F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, laryngitis, and epistaxis.
Days 0-28 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Number of Subjects With Medically-attended Lower Respiratory Illnesses (MA-LRIs)
Ramy czasowe: Days 0 to 180 days after final dose or the end of the RSV season, whichever was later
An MA-LRI was a healthcare provider-confirmed diagnosis of 1 or more of the following: wheezing, pneumonia, croup, rhonchi (not cleared with cough or suctioning), rales, bronchitis, bronchiolitis, apnea.
Days 0 to 180 days after final dose or the end of the RSV season, whichever was later
Number of Participants With Serious Adverse Events (SAEs)
Ramy czasowe: Days 0-28 after any dose
Events resulting in death; were life-threatening; resulted in inpatient hospitalization/prolongation of hospitalization; resulted in persistent or significant disability or incapacity; were a congenital anomaly/birth defect in the offspring of a participant; or were an important medical event that may not have resulted in death, threatened life, or required hospitalization and may have jeopardized the participant and required medical/surgical intervention to prevent one of the above outcomes.
Days 0-28 after any dose
Number of Participants With Significant New Medical Conditions (SNMCs)
Ramy czasowe: Day 0 through 180 days after the final dose or through the end of the RSV season, whichever was later
A SNMC is a newly diagnosed medical condition that is of a chronic, ongoing nature and is assessed by the investigator as medically significant.
Day 0 through 180 days after the final dose or through the end of the RSV season, whichever was later

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Number of Participants Shedding Vaccine-like Virus at Any Time During Study Participation
Ramy czasowe: Days 7, 12, and 28 after each dose and during visits for pre-specified illness symptoms occurring Day 0 through 28-34 days post each dose.
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 7, 12, and 28 after each dose and during visits for pre-specified illness symptoms occurring Day 0 through 28-34 days post each dose.
Number of Participants Shedding Vaccine-like Virus at 7 Days After Dose 1
Ramy czasowe: Days 7-10 after Dose 1 (Dose 1 was on Day 0)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 7-10 after Dose 1 (Dose 1 was on Day 0)
Number of Participants Shedding Vaccine-like Virus at 12 Days After Dose 1
Ramy czasowe: Days 12-18 after Dose 1 (Dose 1 was on Day 0)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 12-18 after Dose 1 (Dose 1 was on Day 0)
Number of Participants Shedding Vaccine-like Virus at 28 Days After Dose 1
Ramy czasowe: Days 28-34 after Dose 1 (Dose 1 was on Day 0)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 28-34 after Dose 1 (Dose 1 was on Day 0)
Number of Participants With Shedding of Vaccine-like Virus on Any Day During Days 0-28 After Dose 1
Ramy czasowe: Days 0-34 after Dose 1 (Dose 1 was on Day 0)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 0-34 after Dose 1 (Dose 1 was on Day 0)
Number of Participants Shedding Vaccine-like Virus at 7 Days After Dose 2
Ramy czasowe: Days 7-10 after Dose 2 (Dose 2 was on Day 48-64)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 7-10 after Dose 2 (Dose 2 was on Day 48-64)
Number of Participants Shedding Vaccine-like Virus at 12 Days After Dose 2
Ramy czasowe: Days 12-18 after Dose 2 (Dose 2 was on Day 48-64)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 12-18 after Dose 2 (Dose 2 was on Day 48-64)
Number of Participants Shedding Vaccine-like Virus at 28 Days After Dose 2
Ramy czasowe: Days 28-34 after Dose 2 (Dose 2 was on Day 48-64)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 28-34 after Dose 2 (Dose 2 was on Day 48-64)
Number of Participants With Shedding of Vaccine-like Virus on Any Day During Days 0-28 After Dose 2
Ramy czasowe: Days 0-34 after Dose 2 (Dose 2 was on Day 48-64)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 0-34 after Dose 2 (Dose 2 was on Day 48-64)
Number of Participants Shedding Vaccine-like Virus at 7 Days After Dose 3
Ramy czasowe: Days 7-10 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 7-10 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Number of Participants Shedding Vaccine-like Virus at 12 Days After Dose 3
Ramy czasowe: Days 12-18 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 12-18 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Number of Participants Shedding Vaccine-like Virus at 28 Days After Dose 3
Ramy czasowe: Days 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Number of Participants With Shedding of Vaccine-like Virus on Any Day During Days 0-28 After Dose 3
Ramy czasowe: Days 0-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Number of participants with nasal wash specimens that were positive for RSV or PIV3 by culture and identified as vaccine-type virus by RT-PCR.
Days 0-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Geometric Mean Titers (GMTs) of Serum Antibodies to RSV at Baseline
Ramy czasowe: Baseline (Day 0 prior to Dose 1)
Pre-dose GMT of serum antibody response to RSV as measured by microneutralization assay. Limit of quantification is 5. For results reported as < 5, a value of 2.5 was imputed.
Baseline (Day 0 prior to Dose 1)
Geometric Mean Titers (GMTs) of Serum Antibodies to RSV at Day 28 Post Dose 1
Ramy czasowe: Day 28-34 after Dose 1 (Dose 1 was on Day 0)
Post dose GMT of serum antibody response to RSV as measured by microneutralization assay. Limit of quantification is 5. For results reported as < 5, a value of 2.5 was imputed.
Day 28-34 after Dose 1 (Dose 1 was on Day 0)
Geometric Mean Titers (GMTs) of Serum Antibodies to RSV at Day 28 Post Dose 2
Ramy czasowe: Day 28-34 after Dose 2 (Dose 2 was on Day 48-64)
Post dose GMT of serum antibody response to RSV as measured by microneutralization assay. Limit of quantification is 5. For results reported as < 5, a value of 2.5 was imputed.
Day 28-34 after Dose 2 (Dose 2 was on Day 48-64)
Geometric Mean Titers (GMTs) of Serum Antibodies to RSV at Day 28 Post Dose 3
Ramy czasowe: Day 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Post dose GMT of serum antibody response to RSV as measured by microneutralization assay. Limit of quantification is 5. For results reported as < 5, a value of 2.5 was imputed.
Day 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies to PIV3 at Baseline
Ramy czasowe: Baseline (Day 0 prior to Dose 1)
Post dose GMT of serum antibody response to PIV3 as measured by HAI assay. Limit of quantification is 4. For results reported as < 4, a value of 2 was imputed.
Baseline (Day 0 prior to Dose 1)
Geometric Mean Titers (GMTs) of Serum HAI Antibodies to PIV3 Day 28 Post Dose 1
Ramy czasowe: Day 28-34 after Dose 1 (Dose 1 was on Day 0)
Post dose GMT of serum antibody response to PIV3 as measured by HAI assay. Limit of quantification is 4. For results reported as < 4, a value of 2 was imputed.
Day 28-34 after Dose 1 (Dose 1 was on Day 0)
Geometric Mean Titers (GMTs) of Serum HAI Antibodies to PIV3 Day 28 Post Dose 2
Ramy czasowe: Day 28-34 after Dose 2 (Dose 2 was on Day 48-64)
Post dose GMT of serum antibody response to PIV3 as measured by HAI assay. Limit of quantification is 4. For results reported as < 4, a value of 2 was imputed.
Day 28-34 after Dose 2 (Dose 2 was on Day 48-64)
Geometric Mean Titers (GMTs) of Serum HAI Antibodies to PIV3 Day 28 Post Dose 3
Ramy czasowe: Day 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Post dose GMT of serum antibody response to PIV3 as measured by HAI assay. Limit of quantification is 4. For results reported as < 4, a value of 2 was imputed.
Day 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Number of Participants With Seroresponse to RSV 28 Days After Dose 1
Ramy czasowe: Days 28-34 after Dose 1 (Dose 1 was on Day 0)
Seroresponse is equal to or greater than a 4-fold rise in RSV antibody from baseline as measured by microneutralization assay.
Days 28-34 after Dose 1 (Dose 1 was on Day 0)
Number of Participants With Seroresponse to RSV 28 Days After Dose 2
Ramy czasowe: Days 28-34 after Dose 2 (Dose 2 was on Day 48-64)
Seroresponse is equal to or greater than a 4-fold rise in RSV antibody from baseline as measured by microneutralization assay.
Days 28-34 after Dose 2 (Dose 2 was on Day 48-64)
Number of Participants With Seroresponse to RSV 28 Days After Dose 3
Ramy czasowe: Days 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Seroresponse is equal to or greater than a 4-fold rise in RSV antibody from baseline as measured by microneutralization assay.
Days 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Number of Participants With Seroresponse to PIV3 28 Days After Dose 1
Ramy czasowe: Days 28-34 after Dose 1 (Dose 1 was on Day 0)
Seroresponse is equal to or greater than a 4-fold rise in PIV3 antibody from baseline as measured by HAI assay.
Days 28-34 after Dose 1 (Dose 1 was on Day 0)
Number of Participants With Seroresponse to PIV3 28 Days After Dose 2
Ramy czasowe: Days 28-34 after Dose 2 (Dose 2 was on Day 48-64)
Seroresponse is equal to or greater than a 4-fold rise in PIV3 antibody from baseline as measured by HAI assay.
Days 28-34 after Dose 2 (Dose 2 was on Day 48-64)
Number of Participants With Seroresponse to PIV3 28 Days After Dose 3
Ramy czasowe: Days 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)
Seroresponse is equal to or greater than a 4-fold rise in PIV3 antibody from baseline as measured by HAI assay.
Days 28-34 after Dose 3 (Dose 3 was 48-64 days after Dose 2)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 lipca 2007

Zakończenie podstawowe (Rzeczywisty)

1 listopada 2009

Ukończenie studiów (Rzeczywisty)

1 kwietnia 2010

Daty rejestracji na studia

Pierwszy przesłany

26 czerwca 2007

Pierwszy przesłany, który spełnia kryteria kontroli jakości

27 czerwca 2007

Pierwszy wysłany (Oszacować)

28 czerwca 2007

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

19 lipca 2012

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

13 lipca 2012

Ostatnia weryfikacja

1 lipca 2012

Więcej informacji

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj